Browse MYO9B

Summary
SymbolMYO9B
Namemyosin IXB
Aliases CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cell cortex Cytoplasm, perinuclear region Cytoplasm, cytoskeleton Note=In undifferentiated cells colocalizes with F-actin in the cell periphery while in differentiated cells its localization is cytoplasmic with the highest levels in the perinuclear region.
Domain PF00612 IQ calmodulin-binding motif
PF00063 Myosin head (motor domain)
PF00788 Ras association (RalGDS/AF-6) domain
PF00620 RhoGAP domain
Function

Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Binds actin with high affinity both in the absence and presence of ATP and its mechanochemical activity is inhibited by calcium ions (PubMed:9490638). Also acts as a GTPase activator for RHOA (PubMed:9490638, PubMed:26529257). Plays a role in the regulation of cell migration via its role as RHOA GTPase activator. This is regulated by its interaction with the SLIT2 receptor ROBO1; interaction with ROBO1 impairs interaction with RHOA and subsequent activation of RHOA GTPase activity, and thereby leads to increased levels of active, GTP-bound RHOA (PubMed:26529257).

> Gene Ontology
 
Biological Process GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0030048 actin filament-based movement
GO:0035023 regulation of Rho protein signal transduction
GO:0035385 Roundabout signaling pathway
GO:0046578 regulation of Ras protein signal transduction
GO:0051056 regulation of small GTPase mediated signal transduction
Molecular Function GO:0000146 microfilament motor activity
GO:0003774 motor activity
GO:0003779 actin binding
GO:0005096 GTPase activator activity
GO:0005516 calmodulin binding
GO:0008047 enzyme activator activity
GO:0016887 ATPase activity
GO:0017016 Ras GTPase binding
GO:0017048 Rho GTPase binding
GO:0030695 GTPase regulator activity
GO:0031267 small GTPase binding
GO:0043531 ADP binding
GO:0048495 Roundabout binding
GO:0051020 GTPase binding
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0005884 actin filament
GO:0005938 cell cortex
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation
R-HSA-194840: Rho GTPase cycle
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
Summary
SymbolMYO9B
Namemyosin IXB
Aliases CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYO9B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMYO9B
Namemyosin IXB
Aliases CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYO9B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYO9B
Namemyosin IXB
Aliases CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYO9B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.330.229
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3660.861
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3140.854
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1510.623
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0860.976
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4530.904
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1410.731
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2480.899
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0030.999
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7630.657
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0620.677
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.020.728
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYO9B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.317.6-3.31
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 10310100-900.014
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.3033.30.0365
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59400400.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.53.76.80.393
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYO9B
Namemyosin IXB
Aliases CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYO9B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYO9B
Namemyosin IXB
Aliases CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYO9B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYO9B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYO9B
Namemyosin IXB
Aliases CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYO9B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYO9B
Namemyosin IXB
Aliases CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYO9B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYO9B
Namemyosin IXB
Aliases CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYO9B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYO9B
Namemyosin IXB
Aliases CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYO9B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.